Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus MYCIFRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus MYCIFRADIN.
CORDRAN N vs MYCIFRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis by causing misreading of mRNA and incorporation of incorrect amino acids into the growing peptide chain.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
1-2 g orally every 6 hours for 7-14 days. Or 500 mg intramuscularly every 12 hours.
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Terminal elimination half-life is 9–12 hours in patients with normal renal function; may extend to >20 hours in impaired renal function, necessitating dose adjustment.
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Primarily renal excretion of unchanged drug via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours. Minor biliary excretion (<1%) with fecal elimination accounting for <1%.
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic